Back to search

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

Data up to Jan 2025

Published2015
Citations181
References18

Total Citations Per Year

Abstract

References (18)

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

2016 • 29,943 citations

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

2017 • 14,809 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2012 • 11,574 citations

Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

2014 • 4,953 citations

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

2000 • 4,853 citations

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

2002 • 4,625 citations

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

2015 • 2,502 citations

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1999 • 2,380 citations

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

2014 • 2,174 citations

A TALE nuclease architecture for efficient genome editing

2010 • 1,983 citations

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

2015 • 1,354 citations

Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production

2003 • 933 citations

Programmed death ligand-1 expression in non-small cell lung cancer

2013 • 729 citations

B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

2004 • 664 citations

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

2010 • 554 citations

Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study

2012 • 212 citations

Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung

2012 • 179 citations

Programmed death-ligand 1 (PD-L1) expression in various tumor types

2013 • 27 citations

Cited By (0)

No citing papers found in database

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell… (2015) – Applied immunohistochemistry & molecular morphology | Metascience Observatory Explorer